Every 8-K that Cytokinetics Inc. (CYTK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CYTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYTK filings page.
CYTOKINETICS INC (CYTK) reported that its Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy met both dual primary endpoints. At Week 36, aficamten produced statistically significant improvements versus placebo in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and peak oxygen uptake (pVO₂), with treatment effects of 3.0 points (p=0.021) and 0.67 ml/kg/min (p=0.003), respectively. Key secondary endpoints, including NYHA class improvement, composite CPET z-score and NT‑proBNP, also favored aficamten, though left atrial volume index and time to first cardiovascular event did not. Aficamten was generally well-tolerated but showed higher rates of serious adverse events, heart failure events, and LVEF <50% than placebo. Cytokinetics plans to submit a supplemental New Drug Application to the FDA in the fourth quarter of 2026 to expand MYQORZO (aficamten) from obstructive to non-obstructive HCM.
Cytokinetics reported Q2 2026 results highlighted by initial MYQORZO sales and a major equity raise. Total revenues were $28.6 million, driven by $25.3 million in MYQORZO net product revenue and $3.3 million in collaboration revenue, with no license or milestone revenues. Net loss widened to $198.8 million, or $1.50 per share, as selling, general and administrative costs increased with the commercial launch.
The company ended June 30, 2026 with approximately $1.7 billion in cash, cash equivalents and investments, compared to $1.1 billion at March 31, 2026, supported by a public offering of 11,338,028 shares at $71.00 per share that generated about $760.1 million in net proceeds. As of quarter end, over 700 healthcare providers had prescribed MYQORZO, approximately 1,500 patients had been dispensed therapy and over 80% of patients on therapy were on paid prescriptions. Cytokinetics announced positive Phase 3 ACACIA-HCM results in non-obstructive hypertrophic cardiomyopathy and plans to file a supplemental NDA in the fourth quarter of 2026, while raising its 2026 GAAP combined R&D and SG&A expense guidance to $860–$890 million.
Cytokinetics, Incorporated reported the results of its Annual Meeting of Stockholders held on May 27, 2026. Stockholder participation was high, with 116,125,730 shares represented, or 93.47% of the 124,237,822 shares entitled to vote, establishing a quorum.
Stockholders elected three Class I directors to three-year terms: Edward M. Kaye, M.D., Wendell Wierenga, Ph.D., and Nancy J. Wysenski. They also approved an amendment and restatement of the 2015 Employee Stock Purchase Plan to increase the authorized shares reserved for issuance under the plan by 1,000,000 shares of common stock.
Investors ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers.
Cytokinetics, Incorporated entered into an underwriting agreement for a public offering of 9,859,155 shares of its common stock at a public offering price of $71.00 per share.
The underwriters received a 30-day option to buy up to an additional 1,478,873 shares, which they fully exercised on May 7, 2026. After underwriting discounts, commissions and estimated expenses, net proceeds to Cytokinetics from the offering are approximately $760.2 million, providing substantial new capital to the company.
Cytokinetics, Incorporated furnished a corporate presentation highlighting the launch of MYQORZO (aficamten), its cardiovascular pipeline and its financial position. The company reported about $1.1 billion in cash, cash equivalents and investments as of March 31, 2026 and described additional access to capital through Royalty Pharma arrangements.
The presentation emphasizes MYQORZO’s FDA approval for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), recent U.S., China and EU launches, and key launch metrics such as REMS-certified prescribers, patient uptake and payer coverage. It also outlines late‑stage programs in non‑obstructive HCM, heart failure with reduced ejection fraction and HFpEF, along with 2026 regulatory and clinical milestones, including an aficamten sNDA PDUFA date of November 14, 2026.
Cytokinetics reported first quarter 2026 results highlighted by the U.S. launch of MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy. Net product revenue from MYQORZO reached $4.8 million over roughly nine weeks, contributing to total revenues of $19.4 million versus $1.6 million a year earlier.
R&D expenses were $95.5 million and SG&A climbed to $104.9 million, driven by launch spending, leading to a net loss of $206.0 million, or $1.67 per share. The company ended March 31, 2026 with about $1.1 billion in cash, cash equivalents and investments.
Management reported strong early adoption of MYQORZO, with over 275 prescribers and about 680 patients on therapy, and positive Phase 3 ACACIA-HCM data in non-obstructive HCM. MYQORZO also gained European Commission approval, and an FDA supplemental NDA for MAPLE-HCM was accepted with a PDUFA date of November 14, 2026.
Cytokinetics reported fourth-quarter and full-year 2025 results as it transitions into a commercial-stage company with MYQORZO. Revenue reached $88.0 million for 2025, up from $18.5 million in 2024, driven by $52.4 million from a technology transfer to Bayer and $15.0 million of MYQORZO approval milestones under the Sanofi agreement.
The company ended 2025 with about $1.22 billion in cash, cash equivalents and investments, including $100 million drawn from a Royalty Pharma loan. R&D expenses were $416.0 million and G&A expenses $284.3 million, reflecting clinical advancement and commercial build-out. Net loss widened to $784.9 million, or $(6.54) per share.
MYQORZO (aficamten) was approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., China and Europe, with a U.S. launch underway and a Germany launch planned in Q2 2026. For 2026, the company guided to GAAP combined R&D and SG&A expenses of $830 million to $870 million.
Cytokinetics reported that the European Commission has approved MYQORZO® (aficamten) tablets at 5 mg, 10 mg, 15 mg and 20 mg strengths. The drug is indicated for adult patients with symptomatic, obstructive hypertrophic cardiomyopathy classified as New York Heart Association class II–III. This approval allows Cytokinetics to offer a novel allosteric, reversible inhibitor of cardiac myosin motor activity as a treatment option for this specific heart condition across the European Union.
Cytokinetics, Incorporated reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten). The medicine is a cardiac myosin inhibitor intended to treat symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy in adult patients.
The company stated that a final decision from the European Commission on this marketing application is anticipated in the first quarter of 2026. It also highlighted that statements about potential approval are forward-looking and that actual outcomes may differ from these expectations.
Cytokinetics appointed Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025. His compensation includes a $660,000 annual base salary, a target bonus equal to 50% of salary (75% tied to corporate goals and 25% to individual goals), and a $400,000 signing bonus split into two equal payments, with the initial portion subject to repayment if he resigns or is terminated for cause within one year.
As an inducement equity grant, he will receive restricted stock units with a grant date value of $5,800,000, vesting 40% on the first anniversary, 40% on the second, and 20% on the third, subject to continued service and potential acceleration under the company’s Executive Severance Plan. He will participate in Cytokinetics’ standard benefit, bonus, equity, and severance programs and has entered into the company’s standard indemnification agreement.
Cytokinetics, Incorporated furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company provided these results via a press release dated November 5, 2025, which is included as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, and will not be incorporated into future Securities Act or Exchange Act filings unless expressly stated by the company.
Cytokinetics, Inc. filed an 8-K reporting an Indenture dated September 19, 2025 with U.S. Bank Trust Company, N.A. as trustee that governs the company's 1.75% Convertible Senior Notes due 2031. The filing describes events that would constitute defaults under the Indenture, including failures to pay principal or interest, failures to send required notices, breaches of certain covenants (including on mergers or asset transfers), failures to effect conversions within five business days, uncured defaults under other obligations, specified defaults by significant subsidiaries on indebtedness of at least $50,000,000, and bankruptcy or insolvency events. The filing includes the form of the Note (Exhibit A), press releases dated September 16, 2025, and an interactive cover page XBRL file. The document is signed by Sung H. Lee, Executive VP and CFO.
Cytokinetics states that its New Drug Application for aficamten in obstructive hypertrophic cardiomyopathy is under ongoing regulatory review, and that timing of any approval, final labeling, and the need for a REMS program or other limitations remain uncertain. The company highlights that such regulatory outcomes could affect the commercial prospects for aficamten and could also influence its ability to draw funds under an existing Loan Agreement if conditions are not met. The filing reiterates these are forward-looking statements that speak only as of the report date and that the company may not update them except as required by law.
Cytokinetics, Incorporated filed an amended current report to correct a missing hyperlink to a press release about new data for its drug candidate aficamten. The press release covers additional aficamten results presented at the European Society of Cardiology Congress 2025 in Madrid.
The data include a pre-specified analysis from the MAPLE-HCM study on how aficamten affects heart structure and function, published in the Journal of the American College of Cardiology, and a Late Breaking Clinical Science presentation on atrial fibrillation incidence and impact associated with aficamten, published in Heart Rhythm.
Cytokinetics, Incorporated filed a report to highlight a key clinical milestone. The company announced that the primary results from its MAPLE-HCM study, which compares metoprolol with aficamten in patients with left ventricular outflow tract (LVOT) obstruction and hypertrophic cardiomyopathy (HCM), were presented in a Hot Line Session at the European Society of Cardiology Congress 2025 in Madrid, Spain. At the same time, these results were published in The New England Journal of Medicine, underscoring the scientific importance of the data. A full press release describing this announcement is included as Exhibit 99.1, giving more detail on the study and its findings.
Cytokinetics, Incorporated reported that its Board of Directors appointed James M. Daly as a Class III director effective August 19, 2025, with a term running through the company’s 2028 annual stockholders’ meeting. He will also serve on the Board’s Compliance Committee, and the Board has determined he is independent under SEC rules, Nasdaq standards and the company’s governance guidelines. The company states there are no related-party transactions requiring disclosure.
Mr. Daly will receive standard non-employee director compensation, including a $50,000 annual cash retainer for Board service and $7,500 annually for Compliance Committee service, both pro-rated for partial periods. He is also eligible for an annual equity award of restricted stock units and stock options with a combined grant date fair value of $440,000. In addition, on the effective date he received an initial stock option to purchase 27,450 shares, valued at $700,000, vesting monthly over three years, subject to continued Board service, and the company entered into its standard indemnification agreement with him.